key: cord-0737393-htqr923f
authors: al Fatly, Z.; Betjes, M.G.H.; Messchendorp, A.L.; Sanders, J.S.F.; Reinders, M.E.J.; Kho, M.M.L.; de Weerd, A.E.
title: COVID-19 vaccination response in kidney transplant recipients with and without mycophenolate mofetil: follow-up of a randomized controlled trial.
date: 2022-04-07
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2022.04.002
sha: cdefdc74d04076e3703063c44906a17b5476af9c
doc_id: 737393
cord_uid: htqr923f

nan

Antimetabolite therapy is considered a risk factor for poor vaccination response to COVID-19 vaccination 1, 2 . We have performed a randomized controlled trial in immunologically low risk kidney transplant recipients comparing tacrolimus and mycophenolate mofetil (TAC/MMF) to TAC monotherapy (TACmono) (EudraCT nr.: 2014-001372-66).

Antibody-based immune responses to COVID-19 vaccination were investigated as part of the RECOVAC Antibody study (EudraCT nr.: 2021-001520-18). We determined response to COVID-19 vaccination Table S1 ). Median SARS-CoV-2 Spike S1-specific IgG antibody levels were 37.3 BAU/ml in TAC/MMF (5 non, 7 low, 1 responder) and 715.6 BAU/ml in TACmono (1 non, 6 low, 7 responders, p =0.004, Figure 1 ). Of note is that antibody levels of >1000 BAU/ml, as a presumed threshold for protection against Omicron (B.1.1.529), was reached in 1/13 TAC/MMF and 7/14 TACmono patients (p=0.03).

In this controlled study mycophenolate mofetil on top of tacrolimus severely hampered serological response to SARS-CoV-2 vaccination.

The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

Risk factors associated with poor response to COVID-19 vaccination in kidney transplant recipients

Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

Figure 1: SARS-CoV-2 serological vaccination respons (jpg)

SARS-CoV-2 serological vaccination respons in TACmono vs TAC/MMF 4-8 weeks after vaccination. TACmono: tacrolimus monotherapy. TAC/MMF: tacrolimus and mycophenolate mofetil therapy

The authors declare that there is no conflict of interest.